{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:36:01Z","timestamp":1772120161390,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100016318","name":"Cerus Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016318","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40258-018-0409-3","type":"journal-article","created":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T22:26:29Z","timestamp":1532989589000},"page":"889-899","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model"],"prefix":"10.1007","volume":"16","author":[{"given":"Katherine M.","family":"Prioli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie Katz","family":"Karp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina M.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Chrebtow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay H.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura T.","family":"Pizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,31]]},"reference":[{"key":"409_CR1","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1111\/trf.13644","volume":"56","author":"KW Chung","year":"2016","unstructured":"Chung KW, Basavaraju SV, Mu Y, van Santen KL, Haass KA, Henry R, et al. Declining blood collection and utilization in the United States. Transfusion. 2016;56:2184\u201392.","journal-title":"Transfusion"},{"key":"409_CR2","volume-title":"Toward a sustainable blood supply in the United States: an analysis of the current system and alternatives for the future","author":"AW Mulcahy","year":"2016","unstructured":"Mulcahy AW, Kapinos KA, Briscombe B, Uscher-Pines L, Chaturvedi R, Case SR, et al. Toward a sustainable blood supply in the United States: an analysis of the current system and alternatives for the future. Santa Monica: RAND Corporation; 2016."},{"key":"409_CR3","unstructured":"Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion. FDA draft guidance for industry, March 2016. \n                    https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/guidancecomplianceregulatoryinformation\/guidances\/blood\/ucm425952.pdf\n                    \n                  . Accessed 17 Feb 2017."},{"key":"409_CR4","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1111\/j.1537-2995.2012.03928.x","volume":"53","author":"S Kleinman","year":"2013","unstructured":"Kleinman S, Reed W, Stassinopoulos A. A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States. Transfusion. 2013;53:1603\u201318.","journal-title":"Transfusion"},{"key":"409_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1537-2995.2009.02460.x","volume":"50","author":"LJ Dumont","year":"2010","unstructured":"Dumont LJ, Kleinman S, Murphy JR, Lippincott R, Schuyler R, Houghton J, et al. Screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results. Transfusion. 2010;50:589\u201399.","journal-title":"Transfusion"},{"key":"409_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1423-0410.2008.01051.x","volume":"95","author":"WG Murphy","year":"2008","unstructured":"Murphy WG, Foley M, Doherty C, Tierney G, Kinsella A, Salami A, et al. Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sang. 2008;95:13\u20139.","journal-title":"Vox Sang."},{"key":"409_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-3148.2010.01037.x","volume":"21","author":"S Pearce","year":"2011","unstructured":"Pearce S, Rowe GP, Field SP. Screening of platelets for bacterial contamination at the Welsh blood service. Transfus Med. 2011;21:25\u201332.","journal-title":"Transfus Med"},{"key":"409_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1423-0410.2010.01432.x","volume":"100","author":"G Walther-Wenke","year":"2011","unstructured":"Walther-Wenke G, Wirsing von Konig CH, Daubener W, Heiden M, Hoch J, Hornei B, Volkers P, Working Party on Bacteria Safety in Transfusion Medicine ABotGMoHB. Monitoring bacterial contamination of blood components in Germany: effect of contamination reduction measures. Vox Sang. 2011;100:359\u201366.","journal-title":"Vox Sang"},{"key":"409_CR9","unstructured":"Recommendations for donor screening, deferral, and product management to reduce the risk of transfusion-transmission of Zika Virus. FDA guidance for industry, August 2016. \n                    https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/guidancecomplianceregulatoryinformation\/guidances\/blood\/ucm518213.pdf\n                    \n                  . Accessed 28 Aug 2016."},{"key":"409_CR10","doi-asserted-by":"publisher","first-page":"678645","DOI":"10.1155\/2013\/678645","volume":"2013","author":"G Anez","year":"2013","unstructured":"Anez G, Rios M. Dengue in the United States of America: a worsening scenario? Biomed Res Int. 2013;2013:678645.","journal-title":"Biomed Res Int"},{"key":"409_CR11","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1111\/trf.12790","volume":"54","author":"LR Petersen","year":"2014","unstructured":"Petersen LR, Epstein JS. Chikungunya virus: new risk to transfusion safety in the Americas. Transfusion. 2014;54:1911\u20135.","journal-title":"Transfusion"},{"issue":"Suppl 2","key":"409_CR12","doi-asserted-by":"publisher","first-page":"1S","DOI":"10.1111\/j.1537-2995.2009.02279.x","volume":"49","author":"SL Stramer","year":"2009","unstructured":"Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion. 2009;49(Suppl 2):1S\u201329S.","journal-title":"Transfusion"},{"key":"409_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.15585\/mmwr.mm6626a2","volume":"66","author":"E Stein","year":"2017","unstructured":"Stein E, Elbadawi LI, Kazmierczak J, Davis JP. Babesiosis surveillance\u2014Wisconsin, 2001\u20132015. MMWR Morb Mortal Wkly Rep. 2017;66:687\u201391.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10 Pt 2","key":"409_CR14","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1111\/trf.12371","volume":"53","author":"SL Stramer","year":"2013","unstructured":"Stramer SL, Dodd RY, AABB Transfusion-Transmitted Diseases Emerging Infectious Diseases Subgroup. Transfusion-transmitted emerging infectious diseases: 30\u00a0years of challenges and progress. Transfusion. 2013;53(10 Pt 2):2375\u201383.","journal-title":"Transfusion."},{"issue":"8","key":"409_CR15","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1086\/529143","volume":"46","author":"MR Jacobs","year":"2008","unstructured":"Jacobs MR, Good CE, Lazarus HM, Yomtovian RA. Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets. Clin Infect Dis. 2008;46(8):1214\u201320.","journal-title":"Clin Infect Dis."},{"key":"409_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood-2015-07-655944","volume":"127","author":"H Hong","year":"2016","unstructured":"Hong H, Xiao W, Lazarus HM, Good CE, Maitta RW, Jacobs MR. Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. Blood. 2016;127:496\u2013502.","journal-title":"Blood"},{"issue":"4","key":"409_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ajcp\/aqx167","volume":"149","author":"J Corean","year":"2018","unstructured":"Corean J, Al-Tigar R, Pysher T, Blaylock R, Metcalf RA. Quality improvement after multiple fatal transfusion-transmitted bacterial infections. Am J Clin Pathol. 2018;149(4):293\u20139.","journal-title":"Am J Clin Pathol."},{"key":"409_CR18","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1056\/NEJMp1500154","volume":"372","author":"EL Snyder","year":"2015","unstructured":"Snyder EL, Stramer SL, Benjamin RJ. The safety of the blood supply: time to raise the bar. N Engl J Med. 2015;372:1882\u20135.","journal-title":"N Engl J Med"},{"key":"409_CR19","unstructured":"The INTERCEPT Blood System for Platelets Package Insert. Cerus Corporation; 2018. Available online at\u00a0\n                    https:\/\/intercept-usa.com\/images\/resources\/Package_Inserts\/INTERCEPT_Blood_System_INT2530B_DS_Package_Insert_May-2018.pdf\n                    \n                  . \u00a0Accessed 01 June 2018."},{"key":"409_CR20","unstructured":"Standards for Blood Banks and Transfusion Services. 30th ed. AABB; 2016. Available at\u00a0\n                    https:\/\/marketplace.aabb.org\/ebusiness\/Default.aspx?TabID=251&productId=12991997\n                    \n                  .\u00a0 Accessed 27 Apr 2016."},{"key":"409_CR21","unstructured":"Platelet PGD Test Package Insert. Verax Biomedical; P00583 Rev. G,2015\/06."},{"key":"409_CR22","unstructured":"Lyons NM, Prioli KM, Pizzi LT. Cost of platelet purchase and production: a survey of US Hospitals. Poster presentation at the 22nd annual international meeting of the international society for pharmacoeconomics and outcomes research; 20\u201324 May 2017: Boston, MA."},{"key":"409_CR23","unstructured":"Bureau of Labor Statistics (BLS). May 2015 National Occupational Employment and Wage Estimates. Available at \n                    https:\/\/www.bls.gov\/oes\/2015\/may\/oessrcst.htm\n                    \n                  .\u00a0 Accessed 15 Nov 2016."},{"key":"409_CR24","unstructured":"Employer costs for employee compensation. 2016. \n                    http:\/\/www.bls.gov\/news.release\/pdf\/ecec.pdf\n                    \n                  . Accessed 15 Nov 2016."},{"issue":"5","key":"409_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40258-016-0255-0","volume":"14","author":"KM Prioli","year":"2016","unstructured":"Prioli KM, Pizzi LT, Karp JK, Galanis T, Herman JH. Plasma cost focus group. cost of purchased versus produced plasma from donor recruitment through transfusion. Appl Health Econ Health Policy. 2016;14(5):609\u201317.","journal-title":"Appl Health Econ Health Policy"},{"key":"409_CR26","unstructured":"National Blood Collection, Utilization, and Patient Blood Management Survey Report. AABB; 2013.\u00a0 Available at:\u00a0\n                    http:\/\/www.aabb.org\/research\/hemovigilance\/bloodsurvey\/Documents\/2013-AABB-Blood-Survey-Report.pdf\n                    \n                  .\u00a0 Accessed 9 Jan 2017."},{"issue":"10","key":"409_CR27","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/trf.13149","volume":"55","author":"J McCullough","year":"2015","unstructured":"McCullough J, Goldfinger D, Gorlin J, Riley WJ, Sandhu H, Stowell C, et al. Cost implications of implementation of pathogen-inactivated platelets. Transfusion. 2015;55(10):2312\u201320.","journal-title":"Transfusion."},{"issue":"5","key":"409_CR28","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/j.1537-2995.2008.02048.x","volume":"49","author":"S Kleinman","year":"2009","unstructured":"Kleinman S, Dumont LJ, Tomasulo P, Bianco C, Katz L, Benjamin RJ, et al. The impact of discontinuation of 7-day storage of apheresis platelets (PASSPORT) on recipient safety: an illustration of the need for proper risk assessments. Transfusion. 2009;49(5):903\u201312.","journal-title":"Transfusion."},{"issue":"1","key":"409_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/trf.12232","volume":"54","author":"E Girona-Llobera","year":"2014","unstructured":"Girona-Llobera E, Jimenez-Marco T, Galmes-Trueba A, Muncunill J, Serret C, Serra N, et al. Reducing the financial impact of pathogen inactivation technology for platelet components: our experience. Transfusion. 2014;54(1):158\u201368.","journal-title":"Transfusion."},{"key":"409_CR30","unstructured":"Agency for Healthcare Research and Quality HCUPNet.\u00a0Available at:\u00a0 \n                    http:\/\/hcupnet.ahrq.gov\n                    \n                  . Accessed 27 Nov 2016."},{"key":"409_CR31","unstructured":"SwissMedic haemovigilance annual reports, 2010\u20132015.\u00a0 Available at \n                    https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/humanarzneimittel\/market-surveillance\/haemovigilance\/publications.html\n                    \n                  .\u00a0 Accessed 4 Jan 2017."},{"key":"409_CR32","unstructured":"Rapports d'activit\u00e9 h\u00e9movigilance\/Hemovigilance Activity Reports, 2006-2015. Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9\/French National Agency for Medicine and Health Product Safety.\u00a0\u00a0Available at:\u00a0\n                    http:\/\/ansm.sante.fr\/Mediatheque\/Publications\/Bilans-Rapports-d-activite-Bilans-et-rapports-d-activite#folder_26762\n                    \n                  .\u00a0 Accessed 4 Jan 2017."},{"issue":"12","key":"409_CR33","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1111\/trf.14284","volume":"57","author":"RJ Benjamin","year":"2017","unstructured":"Benjamin RJ, Braschler T, Weingand T, Corash LM. Hemovigilance monitoring of platelet septic reactions with effective bacterial protection systems. Transfusion. 2017;57(12):2946\u201357.","journal-title":"Transfusion."},{"key":"409_CR34","unstructured":"Hospital outpatient prospective payment: notice of final rulemaking (NFRM) with comment period. \n                    https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/HospitalOutpatientPPS\/Hospital-Outpatient-Regulations-and-Notices-Items\/CMS-1678-FC.html?DLPage=1&DLEntries=10&DLSort=2&DLSortDir=descending\n                    \n                  . Accessed 30 Nov 2017."},{"key":"409_CR35","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/trf.13577","volume":"56","author":"NM Dunbar","year":"2016","unstructured":"Dunbar NM, Dumont LJ, Szczepiorkowski ZM. How do we implement day 6 and day 7 platelets at a hospital-based transfusion service? Transfusion. 2016;56:1262\u20136.","journal-title":"Transfusion"},{"key":"409_CR36","unstructured":"Larson R, Aronson CA. Enhanced platelet bacterial screening in an eight-hospital system. AP52. AABB annual meeting; Oct 2017: San Diego, CA."},{"key":"409_CR37","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1111\/trf.14216","volume":"57","author":"JW Li","year":"2017","unstructured":"Li JW, Brecher ME, Jacobson JL, Harm SK, Chen D, El-Gamil A, et al. Addressing the risk of bacterial contamination in platelets: a hospital economic perspective. Transfusion. 2017;57:2321\u20138.","journal-title":"Transfusion"},{"issue":"1","key":"409_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/vox.12456","volume":"112","author":"M Amato","year":"2017","unstructured":"Amato M, Schennach H, Astl M, Chen CY, Lin JS, Benjamin RJ, et al. Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre. Vox Sang. 2017;112(1):47\u201355.","journal-title":"Vox Sang."},{"key":"409_CR39","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1111\/j.1537-2995.2009.02151.x","volume":"49","author":"JC Osselaer","year":"2009","unstructured":"Osselaer JC, Doyen C, Defoin L, Debry C, Goffaux M, Messe N, et al. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion. 2009;49:1412\u201322.","journal-title":"Transfusion"},{"key":"409_CR40","unstructured":"Mendez B, McCable E, DelMonte J, Becker JL. The effects of PAS and PR on platelet use. CP311. Poster presentation at AABB; Oct 2017: San Diego, CA."},{"key":"409_CR41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jinf.2016.11.006","volume":"74","author":"H Arefian","year":"2017","unstructured":"Arefian H, Heublein S, Scherag A, Brunkhorst FM, Younis MZ, Moerer O, et al. Hospital-related cost of sepsis: a systematic review. J Infect. 2017;74:107\u201317.","journal-title":"J Infect"},{"issue":"3","key":"409_CR42","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/MLR.0000000000000481","volume":"54","author":"SL Jones","year":"2016","unstructured":"Jones SL, Ashton CM, Kiehne LB, Nicolas JC, Rose AL, Shirkey BA, et al. Outcomes and resource use of sepsis-associated stays by presence on admission, severity, and hospital type. Med Care. 2016;54(3):303\u201310.","journal-title":"Med Care."},{"key":"409_CR43","unstructured":"Navy wife who lost kidneys after giving birth awarded $24.7\u00a0M. \n                    https:\/\/www.usnews.com\/news\/best-states\/hawaii\/articles\/2018-03-08\/navy-wife-who-lost-kidneys-after-giving-birth-awarded-247m\n                    \n                  . Accessed 5 Mar 2018."},{"key":"409_CR44","unstructured":"FDA Blood Products Advisory Committee 2017. Meeting materials. \n                    https:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/BloodProductsAdvisoryCommittee\/ucm543914.htm\n                    \n                  . Accessed 5 Mar 2018."},{"key":"409_CR45","unstructured":"National Blood Collection and Utilization in the United States (NBCUS) report. Presented at the AABB annual meeting; 22\u201325 Oct 2016: Orlando, FL."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-018-0409-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-018-0409-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-018-0409-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T16:05:03Z","timestamp":1600272303000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-018-0409-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,31]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["409"],"URL":"https:\/\/doi.org\/10.1007\/s40258-018-0409-3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733833692.793569571","asserted-by":"object"}]},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,31]]},"assertion":[{"value":"31 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The transfusion service survey dataset generated and analyzed during the current study is not publicly available because hospital respondents were assured of confidentiality, and responses, even when anonymized, could be used to identify respondents. Aggregated survey results are available from the corresponding author upon reasonable request. The model generated during the current study is not publicly available because it is exclusively licensed by Cerus Corporation, but hospitals and\/or interested readers can arrange a personalized demonstration of the model through Ms. Chrebtow (vchrebtow@cerus.com) upon reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Ms. Chrebtow is employed by Cerus Corporation, and Dr. Pizzi and Ms. Prioli have served as consultants to Cerus Corporation. Vera Chrebtow and Laura T. Pizzi: CERUS Corporation\u2019s sponsorship of the project to Rutgers University covered model development and reporting. Katherine M. Prioli has no major conflicts of interest to declare, however she received a modest honorarium and travel expenses for presenting model results at the Society for the Advancement of Blood Management (SABM) 2017 annual conference. Dr. Karp, Dr. Herman, and Dr. Lyons have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work was supported by a Grant from Cerus Corporation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"As this study involves model construction and does not constitute human subjects research, it was granted exemption from Institutional Review Board (IRB) review. For the assumptions that were informed by a survey fielded to hospital transfusion service directors, the survey was preceded by text informing respondents of the purpose of the study and contact information for the Principal Investigator. IRB review and formal informed consent for this survey were not required because the survey questions pertained to institutional practices and did not include any respondent- or patient-specific information.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}}]}}